Trial of the Week: MENDS2
John Devlin highlights the MENDS2 study in this May Trial of the Week.
Pharmacy to Dose: The Critical Care Podcast
Audio is streamed directly from the publisher (traffic.megaphone.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Trial of the Week: MENDS2
Special Guest: John Devlin, PharmD, BCCCP, MCCM, FCCP @devlinpharmd
03:20 – PADIS background and research introduction
35:25 – MENDS2 discussion
John Devlin joins to review the May Trial of the Week “Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis” the MENDS2 study, published in NEJM in 2021.
We set the scene by discussing how John developed an interest with PADIS research, discussing PK/PD sedative properties and considerations, landmark trials prior to MENDS2, and how much background work is required for a large RCT.
Then we dive into the MENDS2 trial itself. Any significant findings? Biggest methodologic differences from MENDS2 and previous studies? Most challenging process of blinding? Any potential safety concerns? How to avoid unblinding study patients (and why that’s so important)? Plus, trial fun facts, seeing your name in a NEJM research article, applying MENDS2 findings into daily practice, and so much more.
Reference list: https://pharmacytodose.com/wp-content/uploads/2024/05/mends2-trial-of-the-week-references.pdf
PharmacyToDose.Com
@PharmacyToDose
Learn more about your ad choices. Visit megaphone.fm/adchoices